Strong Performance from AbbVie Call Options as Rinvoq Patent Protection Extended

Upside option positions are delivering exceptional profits in AbbVie Inc. (ABBV).

On September 8, 2025, Market Rebellion’s Unusual Option Activity Service identified the purchase of 5,400 September $210 call options for $1.32 to $1.58, with ABBV shares trading between $208.55-$209.06, significantly exceeding the strike’s previous open interest of 472 contracts.

Those September $210 calls have traded as high as $11.53 today with the stock at $221.35, delivering impressive returns of approximately 630.06% to 773.48% from the initial entry price range of $1.32 to $1.58. Meanwhile, ABBV shares gained approximately 5.87% to 6.12% from their initial trading level around $208.55-$209.06, demonstrating how options can deliver significantly amplified returns compared to simply owning the underlying stock.

This performance illustrates the power of options leverage when the directional thesis proves correct, though it’s important to note that this same leverage can work against traders when market moves go in the opposite direction.

Rinvoq Patent Settlement Drives Record High

The exceptional timing of this ABBV options trade proved even more prescient when AbbVie announced a major patent settlement on September 11th that sent shares to a record high. The company revealed it had reached settlement and license agreements with generic drugmakers that will prevent any U.S. generic entry for Rinvoq until April 2037, assuming pediatric exclusivity is granted.

This represents a significant extension beyond the 2032-2033 patent expiry that analysts had previously anticipated. Rinvoq, used for the treatment of rheumatoid arthritis and other autoimmune diseases, is AbbVie’s second best-selling drug behind Skyrizi, generating $5.97 billion in sales or more than 10% of the company’s total revenue in 2024.

J.P. Morgan analyst Chris Schott noted that the extension gives AbbVie “several more years of runway on one of its key growth drivers,” providing more time to develop experimental drugs ahead of major loss of exclusivity in the mid-2030s. William Blair analyst Matt Phipps estimates that four additional years of exclusivity could add roughly $2 billion to peak-year sales of Rinvoq with the next wave of potential approvals.

Shares of ABBV were las up 4.43% at $221.01.